WithdrawnPhase 2NCT05482334

Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome

Studying Down syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Colorado, Denver
Principal Investigator
Peter Pressman, MD
CU Alzheimer's and Cognition Center
Intervention
Sargramostim for Injection(drug)
Eligibility
18-35 years · All sexes
Timeline
2023 – 2026

Study locations (1)

Collaborators

National Institute on Aging (NIA)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05482334 on ClinicalTrials.gov

Other trials for Down syndrome

Additional recruiting or active studies for the same condition.

See all trials for Down syndrome →

← Back to all trials